1-14 of 14 results for subject:Fampridine
Librarians' tools
- Search time
- 0.193 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Fampridine
- We searched for
- subject_t:Fampridine OR subject_ses:450931
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask His Majesty's Government what are the eligibility criteria for a patient with multiple sclerosis to be prescribed Fampridine for a trial period; and what plans they have to fund ongoing treatment on terms similar to those in Wales, Scotland and Northern Ireland where such a trial shows an improvement in the...
To ask His Majesty's Government what are the eligibility criteria for a patient with multiple sclerosis to be prescribed Fampridine for a trial period; and what plans they have to fund ongoing treatment on terms similar to those in Wales, Scotland and Northern Ireland where such a trial shows an improvement in the...
NHS England published a clinical commissioning policy in July 2026 recommending prolonged-release fampridine as a routine commissioning treatment option for adults in England with multiple sclerosis (MS) and associated walking impairment who meet the defined eligibility criteria: those who score 4 to 7 on the Expanded Disability Status Scale.
Funding for prolonged-release fampridine is now available in England. NHS England began routinely commissioning the treatment from 16 July 2026 for eligible adults with multiple sclerosis and associated walking impairment who meet the policy criteria.
To ask His Majesty's Government whether funding is in place to meet the cost of ongoing treatment with Fampridine for patients with multiple sclerosis in England; and, if not, when will it be.
To ask His Majesty's Government whether funding is in place to meet the cost of ongoing treatment with Fampridine for patients with multiple sclerosis in England; and, if not, when will it be.
NHS England published a clinical commissioning policy in July 2026 recommending prolonged-release fampridine as a routine commissioning treatment option for adults in England with multiple sclerosis (MS) and associated walking impairment who meet the defined eligibility criteria: those who score 4 to 7 on the Expanded Disability Status Scale.
Funding for prolonged-release fampridine is now available in England. NHS England began routinely commissioning the treatment from 16 July 2026 for eligible adults with multiple sclerosis and associated walking impairment who meet the policy criteria.
To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on access to fampridine for people with multiple sclerosis in England.
To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on access to fampridine for people with multiple sclerosis in England.
Health is a devolved matter and decisions on the availability of medicines in the devolved administrations are a matter for their own governments.
Ministers and Department officials have had no recent discussions with the National Institute for Health and Care Excellence (NICE) about access to fampridine. NICE’s updated guideline on the diagnosis and management of multiple sclerosis (MS) in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with MS as it is not found to be a cost-effective treatment at the current list price. NICE keeps its guidance under active surveillance and decisions on whether published guidelines should be updated in light of new evidence are taken by the NICE prioritisation board, chaired by the NICE Chief Medical Officer, in line with its published prioritisation framework. NICE has indicated that it has no current plans to review its recommendations on fampridine.
To ask the Secretary of State for Health and Social Care, whether he has made a comparative assessment of the adequacy of availability of fampridine (fampyra) for patients across the four nations of the UK.
To ask the Secretary of State for Health and Social Care, whether he has made a comparative assessment of the adequacy of availability of fampridine (fampyra) for patients across the four nations of the UK.
Health is a devolved matter and decisions on the availability of medicines in the devolved administrations are a matter for their own governments.
Ministers and Department officials have had no recent discussions with the National Institute for Health and Care Excellence (NICE) about access to fampridine. NICE’s updated guideline on the diagnosis and management of multiple sclerosis (MS) in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with MS as it is not found to be a cost-effective treatment at the current list price. NICE keeps its guidance under active surveillance and decisions on whether published guidelines should be updated in light of new evidence are taken by the NICE prioritisation board, chaired by the NICE Chief Medical Officer, in line with its published prioritisation framework. NICE has indicated that it has no current plans to review its recommendations on fampridine.
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the National Institute for Health and Care Excellence on the prescription of Fampridine as a treatment for MS.
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the National Institute for Health and Care Excellence on the prescription of Fampridine as a treatment for MS.
Ministers and departmental officials have regular discussions with the National Institute for Health and Care Excellence (NICE) on a range of issues, including in relation to its guidelines.
NICE’s guideline on the diagnosis and management of multiple sclerosis in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with multiple sclerosis as it is not found to be a cost-effective treatment.
To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with the National Institute for Health and Care Excellence on access to Fampridine for people with multiple sclerosis.
To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with the National Institute for Health and Care Excellence on access to Fampridine for people with multiple sclerosis.
There have been no specific discussions. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources. NICE was unable to recommend fampridine in its clinical guideline on managing multiple sclerosis which was originally published in 2014 and updated in 2022.
To ask Her Majesty's Government why Fampridine is being banned for new patients but is permitted to continue being prescribed for existing patients.
To ask Her Majesty's Government why Fampridine is being banned for new patients but is permitted to continue being prescribed for existing patients.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service in England on best practice. NICE evaluated the clinical and cost effectiveness of fampridine for use in the management of multiple sclerosis (MS) in 2014 but was unable to recommend it for routine use. NICE is currently updating its clinical guideline on MS and recently consulted on draft guidance. However, it was unable to recommend fampridine to treat mobility problems in people with MS. The independent guideline committee acknowledged that while it is a clinically effective treatment for some patients, at its current price it is not cost effective for the NHS.
NICE will carefully consider comments from stakeholders in finalising its recommendations. It is for local NHS commissioners to make funding decisions on the use of fampridine taking account of NICE’s guidance. The availability of treatments in Scotland and Wales is a matter for the devolved administrations.
To ask Her Majesty's Government why Fampridine is authorised for general NHS use in (1) Scotland, and (2) Wales, but is not permitted for new patients in England.
To ask Her Majesty's Government why Fampridine is authorised for general NHS use in (1) Scotland, and (2) Wales, but is not permitted for new patients in England.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service in England on best practice. NICE evaluated the clinical and cost effectiveness of fampridine for use in the management of multiple sclerosis (MS) in 2014 but was unable to recommend it for routine use. NICE is currently updating its clinical guideline on MS and recently consulted on draft guidance. However, it was unable to recommend fampridine to treat mobility problems in people with MS. The independent guideline committee acknowledged that while it is a clinically effective treatment for some patients, at its current price it is not cost effective for the NHS.
NICE will carefully consider comments from stakeholders in finalising its recommendations. It is for local NHS commissioners to make funding decisions on the use of fampridine taking account of NICE’s guidance. The availability of treatments in Scotland and Wales is a matter for the devolved administrations.
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on access to Fampridine by people with multiple scleroris.
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on access to Fampridine by people with multiple scleroris.
We have had no such discussions. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources.
NICE was unable to recommend fampridine in its clinical guideline on managing multiple sclerosis (MS) which was originally published in 2014. However, NICE is now updating this guideline, which will include reviewing the recommendation on fampridine. NICE expects to publish its draft guidance on the management of MS for consultation in December this year, with final guidance expected on 1 June 2022.
To ask the Secretary of State for Health and Social Care, what assessment the Government has made of the potential cost savings for (a) social care and (b) welfare of making fampridine (fampyra) routinely available on the NHS.
To ask the Secretary of State for Health and Social Care, what assessment the Government has made of the potential cost savings for (a) social care and (b) welfare of making fampridine (fampyra) routinely available on the NHS.
The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service. In developing its recommendations, NICE takes account of all health and publicly funded social care costs and benefits. It does not routinely consider wider societal costs such as the impact on welfare spending.
To ask the Secretary of State for Health and Social Care, what recent assessment has made of the potential merits of using fampridine for the treatment of multiple sclerosis.
To ask the Secretary of State for Health and Social Care, what recent assessment has made of the potential merits of using fampridine for the treatment of multiple sclerosis.
The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources.
NICE was unable to recommend fampridine as an effective use of resources in its clinical guideline on managing multiple sclerosis. However, NICE is now updating this guideline, which will include reviewing the recommendation on fampridine. NICE expects to publish its draft guidance on the management of multiple sclerosis for consultation in December this year, with final guidance expected on 1 June 2022.
To ask the Secretary of State for Health and Social Care, what plans his Department has to authorise GPs to issue prescriptions for Fampridine for multiple sclerosis patients at the standard NHS prescription charge.
To ask the Secretary of State for Health and Social Care, what plans his Department has to authorise GPs to issue prescriptions for Fampridine for multiple sclerosis patients at the standard NHS prescription charge.
It is for the prescribing clinician to decide on the most appropriate course of treatment for their patient. The National Institute for Health and Care Excellence’s (NICE) current recommendation is that fampridine is not a cost-effective treatment for lack of mobility in people with multiple sclerosis. NHS England and NHS Improvement’s commissioning policy concluded in 2016 that there is not enough evidence to make the treatment available at that time. However, NICE is currently updating its guideline on multiple sclerosis, including to take account of new evidence on the effectiveness of fampridine for treating mobility in people with multiple sclerosis. NICE currently expects to publish final updated guidance in July 2022.
To ask the Secretary of State for Health and Social Care, what recent steps his Department has taken to ensure that fampridine is available to people with multiple sclerosis.
To ask the Secretary of State for Health and Social Care, what recent steps his Department has taken to ensure that fampridine is available to people with multiple sclerosis.
NHS England published its policy on Fampridine in July 2016. This states that this is not routinely commissioned for multiple sclerosis (MS). This policy is based on the recommendations from National Institute for Health and Care Excellence in the publication 'Multiple sclerosis: management of multiple sclerosis in primary and secondary care (CG186)’ which recommends that fampridine is not used for MS as it is not a cost-effective option.
The NHS Business Services Authority only collects prescribing data on private prescriptions where the drug prescribed is a controlled drug. Fampridine is not classified as a controlled drug, so the information requested is not collected.
Since 1 April 2013, the NHS England Individual Funding Request (IFR) team has received 21 applications for Fampridine for multiple sclerosis (including Amifampridine/Firdapse; Fampridine/Fampyra; Fampridine SR/Fampyra). None of the applications were approved. It is not possible to distinguish IFR requests specifically from Oxfordshire.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people accessing fampridine through (a) private prescriptions and (b) individual funding requests in (i) Oxfordshire and (ii) England.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people accessing fampridine through (a) private prescriptions and (b) individual funding requests in (i) Oxfordshire and (ii) England.
NHS England published its policy on Fampridine in July 2016. This states that this is not routinely commissioned for multiple sclerosis (MS). This policy is based on the recommendations from National Institute for Health and Care Excellence in the publication 'Multiple sclerosis: management of multiple sclerosis in primary and secondary care (CG186)’ which recommends that fampridine is not used for MS as it is not a cost-effective option.
The NHS Business Services Authority only collects prescribing data on private prescriptions where the drug prescribed is a controlled drug. Fampridine is not classified as a controlled drug, so the information requested is not collected.
Since 1 April 2013, the NHS England Individual Funding Request (IFR) team has received 21 applications for Fampridine for multiple sclerosis (including Amifampridine/Firdapse; Fampridine/Fampyra; Fampridine SR/Fampyra). None of the applications were approved. It is not possible to distinguish IFR requests specifically from Oxfordshire.